

8 Jan 2026

Press Release

EFPIA Japan

EFPIA Japan Appoints John Paul Pullicino as New Vice Chair

European Federation of Pharmaceutical Industries and Associations (EFPIA Japan, Chair: Takahiko Iwaya) announced that John Paul Pullicino (Novartis Pharma K.K.) has been appointed as Vice Chair effective January 2026. His term will run until March 2027. This appointment follows the departure of Kasper Bødker Mejlvang. Vice Chair Takafumi Horii (AstraZeneca K.K.) will remain in his role, continuing to support Chair Iwaya (Sanofi K.K.) together with the newly appointed Vice Chair Pullicino.

“Amid accelerating macro-environmental changes, EFPIA Japan is committed to contributing to the advancement of healthcare in Japan through policy proposals that enable both timely patient access to innovative medicines and vaccines and the sustainability of innovation. We will continue constructive dialogues with stakeholders to identify solutions, leveraging our expertise and insights.” says John Paul Pullicino upon his appointment.

John Paul Pullicino – Biography



With over 20 years' experience in the pharmaceutical industry, John Paul Pullicino began his career as a Medical Representative at Pfizer Australia. He has held positions of increasing responsibility across various sales, marketing and general management leadership roles. Working in positions spanning, local, regional and global responsibility, across diverse Therapeutic Areas and across multiple markets including Australia, New Zealand, Japan, Korea, Hong Kong and Vietnam. John Paul has worked within the Japan pharmaceutical industry for over 5 years, with his first assignment in 2016 and returning to Japan in 2022. His prior position was as Director and Executive Officer, Head of the Oncology Business Unit at Pfizer Japan Inc. He was appointed Country President and Representative Director of Novartis Pharma K.K. in late 2024. Throughout his career, he has gained extensive experience in pharmaceutical industry associations.

About EFPIA Japan (<http://efpia.jp/>)

Established in April 2002, EFPIA Japan represents 24 R&D-based European pharmaceutical companies operating in Japan. In 2024, combined sales from the member companies accounted for approximately 29.4% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines.” EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

About EFPIA (The European Federation of Pharmaceutical Industries and Associations) (<http://www.efpia.eu>)

The European Federation of Pharmaceutical Industries and Association (EFPIA) represents the biopharmaceutical industry operating in Europe. Through its direct membership of 36 national associations, 40 leading pharmaceutical companies, and growing number of small and medium sized enterprises (SMEs), EFPIA’s mission is to create a collaborative environment that enables our members to innovate, discover, develop, and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.

Contact:

Yukie Shimono

EFPIA Japan External Affairs Committee

Tokyo Opera City Tower, 3-20-2 Nishi-Shinjuku, Shinjuku-ku, Tokyo 163-1488, Japan
Sanofi K.K.

Tel: 090-2736-8171

Email: yukie.shimono@sanofi.com